APPLIED THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.39 USD | -4.98% |
|
-7.77% | +31.04% |
| May. 09 | Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 09 | Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000 | MT |
Presentation Operator MessageOperator (Operator)Welcome to Applied Therapeutics' SORD Deficien...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companyâs lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.39
USD
Average target price
11.4
USD
Spread / Average Target
+159.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.04% | 502M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- APLT Stock
- News Applied Therapeutics, Inc.
- Transcript : Applied Therapeutics, Inc. - Special Call
